empagliflozin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“In comparison with control group for non-alcoholic fatty liver disease, empagliflozin treatment shows no substantial impact on ALT (SMD=-0.09; 95% CI=-0.37 to 0.18; P=0.50; Figure 4), AST (SMD=-0.26; 95% CI=-0.53 to 0.02; P=0.07; Figure 5), LDL (SMD=-0.31; 95% CI=-0.74 to 0.11; P=0.15; Figure 6) or TG (SMD=-0.17; 95% CI=-0.54 to 0.19; P=0.35; Figure 7).”
Quoted verbatim from Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 mg daily
- Population
- Patients with non-alcoholic fatty liver disease, pooled across randomized trials of empagliflozin 10 mg daily versus placebo
Effect -0.31 standardised mean difference, 95% CI -0.74 to 0.11
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.2022PMID:36910362Permalink
Keep reading
- Everything the graph holds on empagliflozin
- Every compound studied against LDL cholesterol
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PR76E56G16Q2NPD5PGD0T4